How pharma wants to break the efficacy ceiling in IBD
Despite major shifts in the IBD landscape, most approaches that go beyond targeting inflammation remain in the earlier stages of development.
Features
‘UK commercial clinical trials will double and double again’ – Lord James O’Shaughnessy
Calibrating cold chain systems for cell and gene therapies in a post-pandemic world
Magazine: Digital dilemma in UK’s life sciences job market
Hope for the UK clinical trial landscape but it requires a lot of work
Subcutaneous drugs grant a new lease on life to checkpoint inhibitors
UK life sciences grapple with the job market’s digital dilemma
Cancer treatment uncertainty: European nations struggle with drug shortages
